RenovoRx, Inc. (RNXT)
| Market Cap | 38.07M |
| Revenue (ttm) | 1.12M |
| Net Income (ttm) | -11.17M |
| Shares Out | 45.05M |
| EPS (ttm) | -0.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 470,641 |
| Open | 0.870 |
| Previous Close | 0.870 |
| Day's Range | 0.831 - 0.890 |
| 52-Week Range | 0.701 - 1.450 |
| Beta | 1.22 |
| Analysts | Strong Buy |
| Price Target | 8.25 (+876.33%) |
| Earnings Date | May 14, 2026 |
About RNXT
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California. [Read more]
Financial Performance
In 2025, RenovoRx's revenue was $1.12 million, an increase of 2511.63% compared to the previous year's $43,000. Losses were -$11.17 million, 26.7% more than in 2024.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for RNXT stock is "Strong Buy." The 12-month stock price target is $8.25, which is an increase of 876.33% from the latest price.
News
RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting
MOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
Data Shows TAMP to be a Promising Approach for Local Delivery of Gemcitabine with Reduced Systemic Toxicity in Patients Diagnosed with Locally Advanced Pancreatic Cancer
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum
Patent Expands Protection for the Company's RenovoCath Device, the Novel Dual-Occlusion Catheter-Based System RenovoRx Currently Holds a Strong and Growing Global Intellectual Property Portfolio with...
RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026
RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and More RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and More
RenovoRx Earnings Call Transcript: Q4 2025
2025 marked the first full year of commercial revenue, with $1.1 million generated and a strong gross margin. The company targets tripling its active sites to 36 in 2026, expects $3–$4 million in revenue, and is well-funded following a $10 million private placement.
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
RenovoCath ® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipat...
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
TIGeR-PaC Trial Enrollment Remains on Track for Completion in First Half of 2026, with Final Data Expected in 2027 Select TIGeR-PaC Cancer Centers Now Using RenovoCath ® as a Stand-Alone Device for Dr...
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
Company has the funding, business plan, leadership and infrastructure to propel achievement of upcoming commercial and clinical milestones Company has the funding, business plan, leadership and infras...
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
MOUNTAIN VIEW, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and com...
RenovoRx Announces $10 Million at Market Private Placement
Bolstered Cash Position Expected to Capitalize the Company's Momentum Towards Important Milestones, Including Breakeven Operations and Trial Data
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
MOUNTAIN VIEW, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.
RenovoRx Establishes RenovoCath® Medical Advisory Board
Advisory Board Members Will Provide Strategic Clinical Insights to Further Advance the TAMP™ Therapy Platform in Clinical Indications of High Unmet Medical Need Advisory Board Members Will Provide Str...
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
Appointment Strengthens RenovoRx's C-Suite Leadership to Support Commercial Growth of RenovoCath® Appointment Strengthens RenovoRx's C-Suite Leadership to Support Commercial Growth of RenovoCath®
RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
Results Support TAMP's Novel Approach to Targeted, Pressure-Mediated Chemotherapeutic Delivery and Reinforces its Potential to Provide Individualized, Optimized Drug-Delivery Results Support TAMP's No...
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
MOUNTAIN VIEW, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
MOUNTAIN VIEW, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies, today a...
RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026
CEO Shaun Bagai to Discuss RenovoRx's Commercial and Clinical Program Progress CEO Shaun Bagai to Discuss RenovoRx's Commercial and Clinical Program Progress
RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026
New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx's TAMP Therapy Platform as a Targeted Drug-Delivery Approach
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026
MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc.
RenovoRx Transcript: IAccess Alpha Virtual MicroCap Conference
A two-prong strategy is driving growth: commercializing a novel cancer therapy device and advancing a pivotal phase III trial for pancreatic cancer. Early sales show strong repeat usage, with significant market potential and ramping revenue expected as more centers adopt the technology.
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th
MOUNTAIN VIEW, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and comm...
RenovoRx Transcript: AGP Emerging AgBiotech/Bio-Solutions
A novel localized chemotherapy platform is generating early commercial revenue and strong clinical data, with a phase III trial in pancreatic cancer showing extended survival and reduced toxicity. Expansion plans include new indications, strategic partnerships, and a scalable sales model.
RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th
MOUNTAIN VIEW, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and comm...
RenovoRx Earnings Call Transcript: Q3 2025
TAMP and RenovoCath are gaining traction in the U.S., with $900,000 in YTD revenue and expansion to 14 approved centers. Cash reserves exceed $10 million, supporting ongoing commercialization and clinical trials, with final Phase III data expected in 2027.